June 25 (Reuters) - Aprea Therapeutics Inc APRE.O:
APREA REPORTS ANTI-PROLIFERATIVE RESULTS AND PROMISING EARLY-STAGE CLINICAL DATA FOR NEXT-GENERATION WEE1 INHIBITOR, APR-1051, IN HPV+ HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) IN COLLABORATION WITH MD ANDERSON CANCER CENTER
APREA THERAPEUTICS INC - PHASE 1 UPDATE SHOWS EARLY DISEASE CONTROL IN HPV+ PATIENT
Source text: ID:nGNXbt7Z3h
Further company coverage: APRE.O
((Reuters.Briefs@thomsonreuters.com;))